Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.55 |
| ▸ | NPY1R | P25929 | 6/20 | 0.55 |
| ▸ | NPY2R | P49146 | 4/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199205 | 0.93 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30799916 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL30866920 | 0.90 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29533534 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29560353 | 0.89 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29379362 | 0.89 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30198871 | 0.88 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL30798743 | 0.88 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29732500 | 0.88 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL31383731 | 0.87 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374071-A1 | COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION | DIGNIFY THERAPEUTICS, LLC | 2023-11-23 | — | — | US | disclosed |
| EP-4225771-A1 | COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION | Dignify Therapeutics, LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076815-A1 | COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION | DIGNIFY THERAPEUTICS, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374071-A1 | COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION | VIP, VIPR1, VIPR2 | NPY4R 215/4885NPY1R 199/4885NPY2R 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.